Acadia Pharmaceuticals buy UBS Group AG
Start price
17.10.23
/
50%
€21.80
Target price
17.10.24
€31.28
Performance (%)
-27.32%
Price
26.04.24
€15.62
Summary
This prediction is currently active. The price of Acadia Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -27.32%. This prediction currently runs until 17.10.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Acadia Pharmaceuticals | 0.807% | 0.807% |
| iShares Core DAX® | -0.992% | -3.231% |
| iShares Nasdaq 100 | -0.225% | -3.339% |
| iShares Nikkei 225® | -0.736% | -7.859% |
| iShares S&P 500 | -0.509% | -2.979% |
Comments by UBS_Group_AG for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $33.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat